BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9117214)

  • 21. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
    Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
    J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
    van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
    Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
    Heino A; Aaltomaa S; Ala-Opas M
    Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BTA-TRAK--a useful diagnostic tool in urinary bladder cancer?
    Mahnert B; Tauber S; Kriegmair M; Schmitt UM; Hasholzner U; Reiter W; Hofmann K; Schmeller N; Stieber P
    Anticancer Res; 1999; 19(4A):2615-9. PubMed ID: 10470204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
    de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
    BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
    Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A
    Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
    Davies B; Chen JJ; McMurry T; Landsittel D; Lewis N; Brenes G; Getzenberg RH
    Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
    Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
    Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
    Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
    Lotan Y; Roehrborn CG
    J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost of bladder tumour treatment and follow-up.
    Hedelin H; Holmäng S; Wiman L
    Scand J Urol Nephrol; 2002; 36(5):344-7. PubMed ID: 12487738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
    Jancke G; Damm O; Rosell J; Jahnson S
    Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer.
    Cauberg EC; Kloen S; Visser M; de la Rosette JJ; Babjuk M; Soukup V; Pesl M; Duskova J; de Reijke TM
    Urology; 2010 Sep; 76(3):658-63. PubMed ID: 20223505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer.
    Raitanen MP; Kaasinen E; Lukkarinen O; Kauppinen R; Viitanen J; Liukkonen T; Tammela TL;
    Urology; 2001 Apr; 57(4):680-4. PubMed ID: 11306380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.